D-0201-2021 Class III Terminated

Recalled by SCA Pharmaceuticals — Windsor, CT

FDA drug recall D-0201-2021 was initiated by SCA Pharmaceuticals on Dec 17, 2020 and is designated Class III. Reason for recall: Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit The recall status is terminated (terminated Nov 2, 2021). Affected quantity: 751 syringes.

Recall details

Product Type
Drugs
Report Date
Jan 13, 2021
Initiation Date
Dec 17, 2020
Termination Date
Nov 2, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
751 syringes

Product description

Morphine Sulfate 3 mg/3 mL in 0.9% Sodium Chloride (1mg/mL) CII, Rx Only, 3 ml Single Dose Syringe, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT, 06095, barcode 70004010025

Reason for recall

Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit

Distribution pattern

Product was distributed to hospitals nationwide.

Code information

Lot # 1220023452, BUD 2/7/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0201-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0201-2021. Report a data issue: hello@regdatalab.com.